Anti-Angiogenic Agents for Non-Malignant Brain Tumors

Hawasli, Ammar H.; Rubin, Joshua B.; Tran, David; Adkins, Douglas R.; Waheed, Shahid; Hullar, Timothy E.; Gutmann, David H.; Evans, John J.; Chicoine, Michael R.

doi:10.1055/s-0033-1336173

Cited by 13 publications

(7 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With the advances in genetics, gene therapy has been studied in animal models of both spinal and intracranial meningiomas [ 44 , 45 , 46 , 47 , 48 ]. Thus far however, targeted therapies (ex: anti-VGEF) in the treatment of intracranial meningiomas have not shown definitive results [ 44 , 49 , 50 , 51 ].…”

Section: Resultsmentioning

confidence: 99%

Current Knowledge on Spinal Meningiomas Epidemiology, Tumor Characteristics and Non-Surgical Treatment Options: A Systematic Review and Pooled Analysis (Part 1)

El-Hajj

Pettersson-Segerlind

Fletcher‐Sandersjöö

et al. 2022

Cancers

View full text Add to dashboard Cite

Background: Spinal meningiomas are the most common primary intradural spinal tumors. Although they are a separate entity, a large portion of the knowledge on spinal meningiomas is based on findings in intracranial meningiomas. Therefore, a comprehensive review of all the literature on spinal meningiomas was performed. Methods: Electronic databases were searched for all studies on spinal meningiomas dating from 2000 and onward. Findings of matching studies were pooled to strengthen the current body of evidence. Results: A total of 104 studies were included. The majority of patients were female (72.83%), elderly (peak decade: seventh), and had a world health organization (WHO) grade 1 tumor (95.7%). Interestingly, the minority of pediatric patients had a male overrepresentation (62.0% vs. 27.17%) and higher-grade tumors (33.3% vs. 4.3%). Sensory and motor dysfunction and pain were the most common presenting symptoms. Despite a handful of studies reporting promising findings associated with the use of non-surgical treatment options, the literature still suffers from contradictory results and limitations of study designs. Conclusions: Elderly females with WHO grade 1 tumors constituted the stereotypical type of patient. Compared to surgical alternatives, the evidence for the use of non-surgical treatments is still relatively weak.

show abstract

Section: Resultsmentioning

confidence: 99%

Current Knowledge on Spinal Meningiomas Epidemiology, Tumor Characteristics and Non-Surgical Treatment Options: A Systematic Review and Pooled Analysis (Part 1)

El-Hajj

Pettersson-Segerlind

Fletcher‐Sandersjöö

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…Previous studies have suggested that the therapeutic dose of bevacizumab was 5 or 10 mg/kg (21,22). The relationship between the bevacizumab dose and adverse reactions is unclear (23,24).…”

Section: Treatmentmentioning

confidence: 99%

The benefit of bevacizumab therapy in patients with refractory vasogenic edema caused by brain metastasis from lung and colon cancers

Bai

Zhang²

2022

Front. Oncol.

View full text Add to dashboard Cite

ObjectiveThis retrospective study investigated the efficacy of bevacizumab in refractory brain edema caused by brain metastasis from lung cancer and colon cancer.MethodsA total of 72 patients with refractory brain edema were divided into the lung cancer and colon cancer groups according to their primary tumor. All patients received a single bevacizumab treatment for refractory brain edema. MRI was performed 1 week before the treatment and 4 weeks after the treatment. The edema and tumor volumes were calculated using imaging modalities.ResultsAfter a single bevacizumab treatment, the refractory brain edema of 61 patients was controlled, and the clinical symptoms of 65 patients were improved. The average edema volume before treatment was 201,708.97 ± 61,426.04 mm3, which has decreased to 116,947.01 ± 43,879.16 mm3 after treatment (P < 0.05). After treatment, the edema index decreased from 25.97 ± 7.15 to 17.32 ± 5.24 (P < 0.05).We found that brain edema was controlled in 40 patients (93.02%) in the lung cancer group and 21 patients (72.41%) in the colon cancer group (P<0.05). In addition, 22 patients (88.00%) in the radiotherapy group achieved edema control, compared to 39 (82.98%) in the non-radiotherapy group (P>0.05). Nine patients experienced hypertension after treatment, two patients exhibited decreased platelet counts, and no hemorrhage cases were observed.ConclusionBevacizumab can significantly alleviate refractory brain edema, and there is a significant difference in the efficacy of bevacizumab on refractory brain edema caused by brain metastasis from lung and colon cancers.

show abstract

“…The recommended dose of BV in the previous literature is 5–10 mg/kg. 16 , 20 A few believe that 15 mg/kg is reasonable. 21 The usage of BV in this study was 10 mg/kg.…”

Section: Methodsmentioning

confidence: 99%

Efficacy of Bevacizumab in High-Grade Meningiomas: A Retrospective Clinical Study

Bai¹,

Liu²,

Wen³

2022

NDT

View full text Add to dashboard Cite

Objective We investigated the role of bevacizumab (BV) in high-grade meningiomas (HGMs) by retrospective analysis. Methods We retrospectively analyzed the clinical data of 139 patients with HGMs. The chi-square test was used to compare progression-free survival (PFS) and overall survival (OS) between patients who received BV and those who did not. According to whether they received BV treatment, we divided the patients into the BV group and non-BV group, and the effect of BV on PFS and OS was compared. In addition, we compared Karnofsky performance status (KPS) and steroid doses between the BV and non-BV groups. Results There were statistically differences in PFS and OS between the BV and non-BV groups at 12 and 36 months after surgery (P<0.05). However, there was no significant difference in PFS and OS between the two groups at 60 months postoperatively (P>0.05). Using survival curves drawn by the Kaplan Meier method, we found that the PFS and OS of the BV group were greater than those of the non-BV group, and the difference was statistically significant (P<0.05). Conclusion BV could improve PFS and OS at 12 and 36 months after surgery in patients with HGMs. In addition, BV was associated with lower preoperative steroid use.

show abstract

Anti-Angiogenic Agents for Non-Malignant Brain Tumors

Cited by 13 publications

References 12 publications

Current Knowledge on Spinal Meningiomas Epidemiology, Tumor Characteristics and Non-Surgical Treatment Options: A Systematic Review and Pooled Analysis (Part 1)

Current Knowledge on Spinal Meningiomas Epidemiology, Tumor Characteristics and Non-Surgical Treatment Options: A Systematic Review and Pooled Analysis (Part 1)

The benefit of bevacizumab therapy in patients with refractory vasogenic edema caused by brain metastasis from lung and colon cancers

Efficacy of Bevacizumab in High-Grade Meningiomas: A Retrospective Clinical Study

Contact Info

Product

Resources

About